Literature DB >> 1882273

Intraoperative evaluation of intestinal ischemia: a comparison of methods.

D L Dyess1, B W Bruner, C A Donnell, J J Ferrara, R W Powell.   

Abstract

Methods for evaluating intestinal ischemia include standard clinical criteria, Doppler ultrasonography, and intravenous fluorescein injection. Each has disadvantages, and a combination of methods is often used. The purpose of this study was to determine whether surface oximetry could be used to assess perfusion in an animal whose intestinal diameter approximates that of infants. Reversible arterial, venous, and arteriovenous occlusion was studied in rabbit intestines. After 6 to 8 hours of occlusion, intestinal vascularity was evaluated by the four methods listed. Doppler ultrasonography and surface oximetry were found to be unreliable tools for assessing perfusion in this animal model. We conclude that standard clinical criteria and fluorescein remain the standards for intraoperative evaluation of intestinal perfusion.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1882273     DOI: 10.1097/00007611-199108000-00008

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  4 in total

1.  How to assess intestinal viability during surgery: A review of techniques.

Authors:  Linas Urbanavičius; Piet Pattyn; Dirk Van de Putte; Donatas Venskutonis
Journal:  World J Gastrointest Surg       Date:  2011-05-27

2.  Laparoscopic evaluation of intestinal ischemia using fluorescein and ultraviolet light in a porcine model.

Authors:  J J McGinty; N Hogle; D L Fowler
Journal:  Surg Endosc       Date:  2003-04-28       Impact factor: 4.584

3.  The laparoscopic second look for ischemic bowel disease.

Authors:  S Slutzki; Z Halpern; M Negri; H Kais; A Halevy
Journal:  Surg Endosc       Date:  1996-07       Impact factor: 4.584

4.  Fluorescein-assisted laparoscopy in the identification of arterial mesenteric ischemia.

Authors:  D M Kam; D E Scheeres
Journal:  Surg Endosc       Date:  1993 Mar-Apr       Impact factor: 4.584

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.